Digital Biomanufacturing Market Size

Digital Biomanufacturing Market Analysis

The Digital Biomanufacturing Market size is estimated at USD 21.40 billion in 2024, and is expected to reach USD 37.20 billion by 2029, growing at a CAGR of 11.60% during the forecast period (2024-2029).

The major factors driving the market are the growing adoption of digital biomanufacturing, increasing biologics and biosimilar approvals, and growing demand for biologics, including vaccines, monoclonal antibodies, and gene therapies. Biopharmaceutical manufacturing involves complex and time-consuming processes for the production of high-quality biologics. Hence, to make biomanufacturing time and cost-efficient, pharmaceutical companies are adopting digital biomanufacturing to automate processes and reduce overall human errors in production. Thus, the growing adoption of digital biomanufacturing is expected to drive the market during the forecast period. For instance, in February 2024, Amgen, a biotechnology company, opened a digitally advanced biomanufacturing facility in Ohio, United States. This facility features the latest tech in assembly and final product packaging. According to a release from the local development council, the Columbus Region, this facility is expected to tackle the final manufacturing step for US injectables. Hence, the increasing adoption of digital biomanufacturing is expected to drive the market during the forecast period. Also, the increasing approvals of biologics and biosimilars increase the demand for digital biomanufacturing technologies to improve the manufacturing process by reducing the cost and time, which will drive the market during the forecast period. For instance, in November 2023, the US Food and Drug Administration (FDA) approved the Ixchiq, the first vaccine to prevent the mosquito-borne virus chikungunya. It was approved for use in adults aged 18 years and older. In December 2023, the FDA approved the Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older. Casgevy is the first FDA-approved treatment to utilize a type of novel genome editing technology, signaling an innovative advancement in the field of gene therapy. Hence, the approval of biological and biosimilar products increases the demand for digital biomanufacturing technologies to improve biological products' yield and reduce human manufacturing errors. Hence, the growing adoption of digital biomanufacturing technologies and increasing approval of biologics and biosimilar products are expected to drive the market during the forecast period. However, the lack of skilled professionals to implement digital biomanufacturing solutions is expected to restrain the market during the forecast period.